Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Tisagenlecleucel childhood B-cell acute lymphoblastic leukemia not applicable detail...
JAK2 R938Q Ruxolitinib childhood B-cell acute lymphoblastic leukemia resistant detail...
KMT2A rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
JAK2 rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
JAK3 rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
ABL1 rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
FGFR1 rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
FLT3 rearrange N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
JAK2 mutant N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
JAK3 mutant N/A childhood B-cell acute lymphoblastic leukemia not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02228096 Phase II Tisagenlecleucel Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Completed USA 0
NCT02435849 Phase II Tisagenlecleucel Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed < 6 Months Post All-HSCT. (ELIANA) Active, not recruiting USA | CAN 9
NCT02808442 Phase I UCART19 Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL) Completed USA 3
NCT02877303 Phase II Cyclophosphamide + Dexamethasone + Doxorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Blinatumomab + Inotuzumab ozogamicin Blinatumomab + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Ofatumumab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Vincristine Sulfate Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia Recruiting USA 0
NCT02981628 Phase II Inotuzumab ozogamicin Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Recruiting USA 1
NCT03595917 Phase I Asciminib + Dasatinib + Prednisone ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML Recruiting USA 0
NCT03605589 Phase I Blinatumomab + Pembrolizumab Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma Withdrawn USA 0
NCT03642626 Phase II Cyclophosphamide + Fludarabine + Tisagenlecleucel axicabtagene ciloleucel + Cyclophosphamide + Fludarabine MT2017-45: CAR-T Cell Therapy for Heme Malignancies Recruiting USA 0
NCT03913559 Phase II Inotuzumab ozogamicin Cytarabine + Hydrocortisone + Methotrexate Acetaminophen + Diphenhydramine + Methylprednisolone Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia Recruiting USA 0
NCT03959085 Phase III Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate Inotuzumab ozogamicin Cytarabine + Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Cytarabine + Daunorubicin + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Inotuzumab ozogamicin + Methotrexate Methotrexate + Pegaspargase + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisolone + Vincristine Sulfate Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Recruiting USA | CAN 3